BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4327 related articles for article (PubMed ID: 17458893)

  • 21. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
    Conley BA; Wright JJ; Kummar S
    Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting aberrant chromatin structure in colorectal carcinomas.
    Konishi K; Issa JP
    Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetics in prostate cancer: biologic and clinical relevance.
    Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
    Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
    Bar-Sela G; Jacobs KM; Gius D
    Cancer J; 2007; 13(1):65-9. PubMed ID: 17464248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenome: a new target in cancer therapy.
    Giacinti L; Vici P; Lopez M
    Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy.
    Lunke S; El-Osta A
    J Neurochem; 2009 Jun; 109(6):1557-69. PubMed ID: 19383090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
    Bhalla KN
    J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
    Chung YL; Lee MY; Pui NN
    Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic tools in potential anticancer therapy.
    Sebova K; Fridrichova I
    Anticancer Drugs; 2010 Jul; 21(6):565-77. PubMed ID: 20436342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical application of targeting cancer through histone acetylation and hypomethylation.
    Gilbert J; Gore SD; Herman JG; Carducci MA
    Clin Cancer Res; 2004 Jul; 10(14):4589-96. PubMed ID: 15269129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Histone deacetylases: a new class of efficient anti-tumor drugs].
    Mottet D; Castronovo V
    Med Sci (Paris); 2008; 24(8-9):742-6. PubMed ID: 18789222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone modifications as a platform for cancer therapy.
    Espino PS; Drobic B; Dunn KL; Davie JR
    J Cell Biochem; 2005 Apr; 94(6):1088-102. PubMed ID: 15723344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential role of epigenetic therapy in multiple myeloma.
    Smith EM; Boyd K; Davies FE
    Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
    Vaissière T; Sawan C; Herceg Z
    Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 217.